Ship2B Launches a €30 Million Fund to Invest in Pediatrics in Europe

More investment in children’s health. Ship2B launches a new fund of €30 million to invest in European companies in the field of pediatrics, led by the entrepreneur and businessman Marc Ramis, as explained by Maite Fibla, co-founder of Ship2B.

This is the first fund to invest in companies with a social impact in the pediatrics sector in Europe. In the United States, there is a similar initiative, but until now there was none in the Old Continent. The name given to the fund is Montana Impact Fund, although it is true that Ramis and Fibla specify that it is in the process of registering with the National Securities Market Commission (CNMV), “only waiting to be formally approved.”

The Montana Impact Fund will invest in 16-18 pediatric companies that are in the early stages of research. The fund, for a period of ten years, contemplates five years of investment and another five years of disinvestment and arises from the need to improve the quality of life of the child and respond to the unresolved medical needs of the little ones.

Read more about Ship2 B’s newly launched fund and find out the most important business news of the day with the Born2Invest mobile app.

Ship2B collaborates with Marc Ramis and with the Hospital Sant Joan de Déu Barcelona

Ramis leads the fund and contributes his knowledge in the entrepreneurial world in the biotechnology sector. The businessman was the co-founder and CEO of Rejuveron Senescence Therapeutics, Ninevah Therapeutics, and Senolytic Therapeutics. In addition, Ramis is a board member or strategic advisor to Aptadel Therapeutics, Retinset Therapeutics, Gate2Brain, Dive Medical, Oniria Therapeutics, Nanobots Therapeutics, Cebiotex, Cyclomed, and GeneTether. 

In recent years, Ramis has collaborated with the Hospital Sant Joan de Déu Barcelona, ​​getting involved in the pediatric area. Ship2B will rely on the executive and the Catalan medical center for the success of this fund, the latter acting as a collaborator.

As Ramis explained, there is a lot of pediatric development that does not reach the market, with a  significant gap, with the consequence that the big problem is access to financing so that all the direct impact on the health of patients is subsequently generated. children.

Ship2B intends to carry out a first closing at the end of 2023 to begin to undertake the first investments in 2024

The fund is positioned as article nine, in accordance with the  EU Sustainable Finance Disclosures Regulation  (Sfdr), which came into force in 2021. With the Montana Impact Fund, Ship2B intends to carry out a first closing at the end of 2023 to start making the first investments in 2024.

Ship2B launched its first investment vehicle in 2016, with €4.5 million, investing in 23 companies of which they have already divested from three companies. In 2020, the manager launched a €55 million fund to invest in 18 projects. Three years of the investment period have already been completed and there are two years of disinvestment left.

Among the latest investments of the latter fund are projects such as Envita. Last April, the Spanish company specializing in the development of digital tools to individually attend to the elderly closed a financing round of €500,000 led by Ship2B.

__

(Featured image by 8385 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.